NC-DOLE
19.1.2022 18:59:12 CET | Business Wire | Press release
The American-Costa Rican Chamber of Commerce (AmCham) recognized Dole through its daughter company, Standard Fruit Company de Costa Rica S.A., with the Social Responsibility in Action Award in the Employees Category for their project "De la Mano con Dole" — which loosely translates to "Hand-in-Hand with Dole". This year marks the 25th anniversary of the award which was given December 8, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005875/en/
The Hand-in-Hand with Dole project is an initiative that works towards positively impacting the social development of Standard Fruit Company of Costa Rica (aka Dole Costa Rica) employees and their families, using the Business Multidimensional Business Index (bMPI) methodology developed by the University of Oxford.
The bMPI methodology seeks to measure poverty—not only from the traditional way of per capita income —but also by incorporating dimensions such as, access to health, education, housing, work, social protection and 16 other key indicators. This allows the organization to identify gaps in social programs and work towards solving the multidimensional poverty issues confronted by their employees and their relatives.
Dole is the first agribusiness company in the world to apply the bMPI methodology to address the challenges of social development.
During the diagnostic stage of implementation, Dole Costa Rica achieved a participation rate of 87% in response to socioeconomic surveys among its more than 5300 employees, ranking near the highest level of participation among the companies that have applied the method in the country.
Analysis of the discovered “deficiencies” refocused short-term priorities of the company towards the prevention of disease and the health of our employees at the onset of Covid, to longer term strategies of social protection and health. At the end of September 2021, 500 gaps had been closed.
“We are very proud of being the first banana and pineapple producer to implement this system and seeing such positive results for our employees and families here in Costa Rica,” said Mr. Renato Acuña, President of Dole Fresh Fruit Latin America. “The strategies developed in this program, including social counseling and community care projects, seek to meet needs and provide the necessary capacities for better human development.”
For this project, Dole management has prioritized addressing the following needs: people without health insurance; people with disabilities not receiving state assistance; older adults without a pension, people out of the workforce due to family obligations; and households without drinking water.
In applying findings, Dole has established strategic alliances with Horizonte Positivo, a local NGO that leads the implementation of bMPI in Costa Rica, and with Sophia Oxford, an international non-profit organization that seeks to impact the social investment of companies and the lives of their employees. These third-party interpretations and analyses of results, and the proposal of solutions that can positively affect the reduction of multidimensional poverty, are essential to best practices in solution implementation.
In 2020, Dole introduced its three-pillared Sustainability Framework, The Dole Way , and its ongoing commitment For Food, For Nature and For People. Just as Dole Costa Rica was a pioneer more than 20 years ago in the development of global environmental management systems in agriculture to frame its efforts 'For Nature'; at the beginning of this decade the company intends through this project, to innovate in the establishment of a social development platform focused on its most important resource: 'For People'."
About Dole
Dole plc is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education and research. For more information, please visit www.dole.com or www.doleplc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220119005875/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
